PTEN and ovarian carcinoma: For example, the pharmacological inhibitor GW4869, which blocks neutral sphingomyelinase and thereby suppresses exosome biogenesis and release, has been shown to reduce exosomal miR-223 levels, restore PTEN expression, and enhance cisplatin sensitivity in ovarian cancer cells co-cultured with TAMs (35–37).